Overview

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

Status:
Not yet recruiting
Trial end date:
2026-09-20
Target enrollment:
Participant gender:
Summary
This trial is an open-label, multi-center, dose escalation, dose expansion, and cohort expansion phase I/II clinical study of SYHX1903 in patients with relapsed/refractory hematologic malignancies. This trial aims to evaluate the safety, tolerance, pharmacokinetics, and preliminary antitumor activity of SYHX1903 in patients with relapsed/refractory hematologic malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.